Chung-Han Lee 李宗翰, MD/PhD

Physician-Scientist Focused on Biomarker Development and Novel Therapies

[Chung-Han Lee 李宗翰, MD/PhD @ChungHanLee3]

Rarely do I see such flawed analysis in an abstract that it makes me read the full article.

irAEs Can Predict PFS and OS In Patients w/ Metastatic Renal Cell Carcinoma Treated w/ Immune Checkpoint Inhibitors - PubMed (https://t.co/RHPeumd8Vc)

[Sumanta K. Pal, MD, FASCO @montypal]

Very excited to share with you incredibly promising data for #zanzalintinib (#XL092) in patients with #kidneycancer. A million thanks to @kidneycancer for allowing us to present this data in a highlighted oral session at #IKCSNA23! See my slides/thoughts here: (1/9)

[Chung-Han Lee 李宗翰, MD/PhD @ChungHanLee3]

Great to see everyone at ESMO. @KidneyCancer keep up the good work. Our patients need you.

[Kidney Cancer @KidneyCancer]

Enjoyed meeting old friends at #ESMO23, making new connections, seeing practice-changing research, and having lots of great discussions about how to advance #kidneycancer science by and for patients 🤝 see you next year @myESMO!

[Chung-Han Lee 李宗翰, MD/PhD @ChungHanLee3]

Ending my last clinic @MSKCancerCenter with dinner with @IyerGopa and @KotechaMD. So grateful to work 12 years with the best mentor I have ever had, @motzermd. So proud of @KellyNFitz who is starting @UCSF . Excited to start a new chapter of my career on 8/14.

[UroToday.com @urotoday]

The association between FGFR3 alterations and response to platinum-based chemotherapy in locally advanced and metastatic #UrothelialCarcinoma. @IyerGopa @MSKCancerCenter joins @UroCancerMD @VUMCurology in this discussion on UroToday > https://t.co/k7xDR7cTdQ @EUplatinum

[Chung-Han Lee 李宗翰, MD/PhD @ChungHanLee3]

So lucky to have had the chance to work with @KellyNFitz. UCSF is so lucky to have you. We are all expecting great things from you.

[Kelly Fitzgerald @KellyNFitz]

A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week I joined the GU Med Onc faculty group at @UCSFCancer! Owe so much to my mentors @ChungHanLee3 @motzermd and many others, and so excited for what’s to come.

[Kelly Fitzgerald @KellyNFitz]

A life/career update, delayed by a transcontinental move: last month I graduated @MSKCancerCenter fellowship, and this week I joined the GU Med Onc faculty group at @UCSFCancer! Owe so much to my mentors @ChungHanLee3 @motzermd and many others, and so excited for what’s to come.

[VJ Oncology @VJOncology]

🎥@ChungHanLee3 of @MSKCancerCenter discusses combining lenvatinib and pembrolizumab as a first-line treatment for non-clear cell RCC, aiming to provide a new treatment option for this subgroup:

➡️https://t.co/YPnX8QbstF⬅️

#ASCO23 #KCSM #UroOnc #UroSoMe #ImmunoOnc

[Chung-Han Lee 李宗翰, MD/PhD @ChungHanLee3]

RT @BrendanGuercio: Thank u @NicoleKuderer! So appreciative of @BladderCancerUS, who supported work with @IyerGopa @ChungHanLee3 showing as…

[Benjamin L Maughan @maughanonc]

Thanks @SWOG for highlighting #PAPMET2 as the trial of the week. Prior IO trials suggest it is time for a randomized trial. Many have contributed to our understanding of this disease--lets keep moving forward! @AlbigesL @ChungHanLee3 @montypal https://t.co/VR0NfmgmS3

[UroToday.com @urotoday]

#KEYNOTEB61 study reveals promising results of lenvatinib + pembrolizumab combo in non-clear cell #RCC. @ChungHanLee3 @MSKCancerCenter joins @PBarataMD @caseccc to discuss his significant contributions to #KidneyCancer research. #WatchNow > https://t.co/4LTiQYs3t8

[OncLive.com @OncLive]

Longer follow-up data from the Study 111/KN146 showed that lenvatinib and pembrolizumab produced durable responses lasting at least 18 months in many patients with metastatic RCC. @ChungHanLee3 @MSKCancerCenter @KidneyCancer #KCRS23 #kcsm https://t.co/U0NhYCChAe

[OncLive.com @OncLive]

Lenvatinib and pembrolizumab continued to show clinical activity in patients with metastatic RCC, including in subsets of patients who had received or were naïve to checkpoint inhibitors. @ChungHanLee3 @MSKCancerCenter @KidneyCancer #KCRS23 #kcsm https://t.co/Sz8jccbLiG

[CancerNetwork® @CancerNetwrk]

“The responses remained durable in a subset of patients who were previously treated but ICI naïve, but also in patients who received ICIs as prior systemic therapy,” said Chung-Han Lee, MD, PhD. #kicsm | @kidneycan @ChungHanLee3

https://t.co/PWKby9wHeX

[OncLive.com @OncLive]

Lenvatinib/Pembrolizumab Benefit Is Upheld in Advanced RCC, Including ICI-Pretreated and Naïve Subgroups @ChungHanLee3 @MSKCancerCenter @kidneycan #KCRS23 #kcsm https://t.co/yU9CWV30fx

[Laurence Albiges @AlbigesL]

Pleased to share @TheLancetOncol LENVA-PEMBRO across RCC variant histologies: papillary RCC, unclRCC and chromophobe RCC … interim @myESMO #ESMO22 and final @ChungHanLee3 @ASCO #ASCO23

full text: https://t.co/QioxQEiKho
Thanks to all who change
rareRCC pts Tx!

[Kidney Cancer @KidneyCancer]

Special thanks to our superstar #IKCSNA23 planning committee!

@drphil_urology @TiansterZhang @bergsa83 #MariaCarlo #DanGeynisman @ChungHanLee3 #JodieMaranchie @spsutkaMD #KiranVirdee @ZakhariaYousef https://t.co/4UX4C30IGc

[CancerNetwork® @CancerNetwrk]

Pembrolizumab plus lenvatinib yielded anti-tumor activity and a manageable safety profile as a first-line treatment option for patients with advanced non–clear cell renal cell carcinoma regardless of histology. #kicsm #ASCO23 | @ASCO @ChungHanLee3

https://t.co/211UsfZMsn

[Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) @TiansterZhang]

@kidneycancer brings together the #kidneycancer community for research & practice updates twice yearly #IKCS symposia. I have had the privilege to help plan over the years w/ @eric_facs @ChungHanLee3 @BradMcG04 @bergsa83 et al. Save the date for Nov 10-11, 2023 in Nashville!

[Jose Mauricio Mota @motajmsc]

#ASCO2023 Interesting work by @BrendanGuercio, @ChungHanLee3, and colleagues from @MSKCancerCenter showing an association between high fiber intake and prolonged PFS in urothelial and renal cell carcinoma. Validation is warranted. Abstract 4598.